Primary percutaneous coronary intervention (PCI) with routine stenting of the culprit lesion and adjuvant double or triple antithrombotic therapy has significantly improved the immediate and short-term outcomes of ST-segment elevation myocardial infarction (STEMI) [1] [2] [3] [4] . Although stent implantation was shown to reduce the incidence of reocclusion of the related artery and the need for repeat revascularization, it did not eliminate the risk of in-stent restenosis with recurrent myocardial infarction (MI) after PCI [5, 6] . Stent thrombosis (ST) has also remained a rare but serious cause of recurrent MI, usually followed by a shortterm negative impact on mortality and repeat revascularization [7] . In general, ST seems to be associated with worse clinical outcome than MI resultant from native coronary thrombosis [7] . However, in the specific population of patients recovering from a STEMI, it is not clear whether the negative outcome associated with ST is different from that of nonstentrelated recurrent MI (NSRMI) [9, 10] .
Primary percutaneous coronary intervention (PCI) with routine stenting of the culprit lesion and adjuvant double or triple antithrombotic therapy has significantly improved the immediate and short-term outcomes of ST-segment elevation myocardial infarction (STEMI) [1] [2] [3] [4] . Although stent implantation was shown to reduce the incidence of reocclusion of the related artery and the need for repeat revascularization, it did not eliminate the risk of in-stent restenosis with recurrent myocardial infarction (MI) after PCI [5, 6] . Stent thrombosis (ST) has also remained a rare but serious cause of recurrent MI, usually followed by a shortterm negative impact on mortality and repeat revascularization [7] . In general, ST seems to be associated with worse clinical outcome than MI resultant from native coronary thrombosis [7] . However, in the specific population of patients recovering from a STEMI, it is not clear whether the negative outcome associated with ST is different from that of nonstentrelated recurrent MI (NSRMI) [9, 10] .
The main goal of this study was to evaluate the long-term incidence and impact of recurrent MI after PCI for STEMI by comparing long-term outcomes of ST relative to NSRMI.
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Methods

Patient selection, data collection, and clinical follow-up
This is a retrospective analysis from a prospective ongoing single-center acute MI registry. The sole patient inclusion criterion was PCI for STEMI with stent implantation between 2001 and 2007. This study period was selected to permit long-term follow-up. From the 1124 eligible STEMI patients, those who did not receive a stent (n = 87) and those lost to follow-up in the first month after the index hospitalization (n = 12), mainly nonresidents and foreign citizens, were excluded from further analysis (. Fig. 1) . Thus, the study population consisted of 1,025 patients. Clinical, angiographic, and baseline procedural data using standardized definitions were collected and prospectively entered in a dedicated database. Follow-up data were obtained by a structured telephone interview at 1, 12, 36, and 60 months. Also, every hospital readmission was checked by an adjudication team through chart review for occurrence of MI, ST, stroke, coronary revascularization, bleeding, heart failure, arrhythmias, or death. Mortality data were also obtained through the national death index database and the Portuguese National Patient Registry ® .
The local ethics institutional review board approved the study and informed consent was given by all subjects.
Definitions and study outcomes
PCI for STEMI was defined as any PCI attempt in a STEMI setting in the first 12 h after presentation, or 24 h for those with ongoing symptoms or 36 h in cases of cardiogenic shock [11] . Cases of rescue PCI after failed thrombolysis were also included. Procedure success was defined as final Thrombolysis in Myocardial Infarction (TIMI) flow III and lesion residual stenosis < 30 % by visual estimation after stent implantation.
Recurrent MI was defined as any MI occurring after the index PCI for STEMI. These events were diagnosed through standard clinical follow-up by clinicians not necessarily involved in the study. An independent research team validated all events. Using established criteria for MI definition [12] , recurrent MIs were adjudicated whenever a suggestive clinical, ECG, or imaging finding was reported and there was: (1) at least 20 % increase of the cTn value from baseline level for events occurring in the same index STEMI hospitalization or (2) any elevation of cTn value, for events occurring after index STEMI hospitalization. ST was defined according to the Academic Research Consortium criteria [13] as definite (angiographic or pathological confirmation of thrombus, with or without vessel occlusion, associated with the presence of an acute coronary syndrome) or probable (unexplained death within 30 days of stent implantation or recurrent MI in the stented culprit territory Fig. 1 8 Study flow chart. First, occurrence of recurrent MI is determined. Then, long-term prognosis (MACCE) of patients with ST, NSRMI, or no recurrent MI after PCI for STEMI is assessed. Recurrent MI is classified according to time of occurrence after PCI for STEMI as: early = 0-30, late = 31-364, or very late ≥ 365 days.MACE were determined at 60 months after recurrent MI (for patients with ST or NSRMI) or at 60 months after index PCI for STEMI (for patients with no recurrent MI). MACCE major adverse cardiac and cerebrovascular events, MI myocardial infarction, PCI percutaneous coronary intervention, STEMI ST-segment elevation MI, NSRMI nonstent-related recurrent MI, ST stent thrombosis except when there was no visible stent thrombus and an alternative culprit lesion could be identified by angiographic or pathological examination). NSRMI was defined as any MI occurring after the index PCI for STEMI not fulfilling criteria for definite or probable ST.
The first objective of the study was to determine the incidence of recurrent MI (ST or NSRMI) in the first 60 months after PCI for STEMI. Patients were then divided into three groups according to recurrence of MI. Group A: ST; group B: NSRMI; and group C: no reinfarction. The second purpose was to compare the outcomes of patients with ST, NSRMI, or no reinfarction. Occurrence of subsequent major adverse cardiac and cerebrovascular events (MACCE) -all-cause death, reinfarction, cerebrovascular accident, and target vessel revascularization (TVR) -were recorded for each group and only those events occurring in the subsequent period after ST or NSRMI were considered. Therefore, for followup purposes, time 0 was reset on the date of first recurrent MI for groups A and B. For group C time 0 remained the date of index STEMI (. Fig. 1 ). All deaths were defined as cardiac unless unequivocally proved to be noncardiac. In order to determine the impact of the timing of recurrent MI on prognosis, time elapsed after the index MI was used to classify recurrent MI as early (0-30 days), late (31-360 days), or very late (>360 days). Fig. 2 ).
Statistical analysis
Baseline clinical and angiographic characteristics
Clinical and angiographic characteristics of patients who ultimately had ST, NSRMI, or no recurrent MI were fairly balanced at baseline (time of PCI for STEMI; . Table 1) . Despite having a similar number of diseased vessels or treated lesions in the index procedure, patients with ST were significantly more likely to have long lesions and receive more stents than patients with no recurrent MI. However, these differences were not significant between patients with ST and NSRMI. Immediate procedural success was high and similar among the groups (over 93 %). There were also no differences in the rate of no-reflow phenomenon or achievement of complete revascularization.
Clinical outcomes: follow-up
In the hospitalization period relative to indexPCI forSTEMI,mortalitywas5.9 % (61 patients), with two cases of nonfatal acute ST and no case of NSRMI occurred. Long-term survival free from MACCE, all-cause mortality, and cardiac mortality presented through KM curves are shown in . Fig. 3 . Cumulative MACCE in patients with ST was not significantly different from those with NSRMI (. Table 2 ). However, patients free from any recurrent MI had significantly lower cumulative MACCE than those with ST or NSRMI at the end of follow-up (28.8 %, both p < 0.001) and at both landmark time points (all log-rank p < 0.05; . Fig. 3a,b) . The landmarkanalysis showed thatpatients surviving the first month after ST were still at increased risk for cardiac or all-cause mortality relative to the other two groups in the subsequent months (log-rank p < 0.001), but this risk did not persist beyond 1 year nor did it translate into long-term all-cause mortality (cumulative incidence of all cause-mortality 27.8 vs. 26.7 vs. 23.0 %; . Fig. 3c-f) .
Timing of recurrent MI had a different prognostic impact depending on the type of MI (. Table 3 ). Early NSRMI was associated with a lower all-cause mortality risk than early ST (adjusted HR = 0.22, p = 0.02) and at a longer timeto-death interval, 83 months (95 % CI, 70.97-95.33) vs. 39 months (95 % CI, 17.96-60.12), log-rank (p = 0.005).
In a sensitivity analysis, however, if probable STs were reclassified as NSRMI this difference would no longer remain statistically significant (HR = 0.55, 95 % CI, 0.12-2.49; supplemental material). For the late period there was no excess risk associated with the type of recurrent MI (adjusted HR 1.05, p = 0.93). Very late ST was a rather benign event resulting in 
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Discussion
Recurrent MI after STEMI is not infrequent [14, 16, 17] . ST is associated with a dismal prognosis, but currently there is no evidence of the extent to which outcomes are different from other types of recurrent MI after STEMI. To our knowledge, this is the first report comparing long-term clinical outcomes of ST versus NSRMI after PCI for STEMI. Chechi et al. compared outcomes of primary PCI for de novo lesions versus primary PCI for ST [8] . They found that in-hospital mortality was higher for ST patients. However, at baseline, only 11 % of the patients with de novo lesions had prior MI, which was much lower than the 68 % frequency found in patients with ST. Thus, after adjustment for baseline risk, the 6-month survival and MACCE rates did not differ significantly. It has been suggested that long-term prognosis of recurrent MI after PCI for STEMI is probablymore dependent ontiming thanonthe type of MI itself. In the Valsartan in Acute Myocardial Infarction Trial (VALIANT), early recurrent MI was associated with the highest mortality rate [15] . This observation was consistent with the findings reported by Kikkert et al. [5] in a contemporary cohort of 1,700 primary PCItreated patients. In their analysis, a Jshaped curve of mortality was observed with the highest rates in the first day after recurrent MI followed by a recrudescence after 365 days. Recently published data [9] on long-term outcomes after ST show a significantly lower mortality rate for very late ST (14.7 %) than for early ST (29.3 %) or late ST (41.6 %). Our results corroborate these findings. We found that cumulative mortality for early ST (58.8 %) was significantly higher than for late or very late ST (26.7 and 4.54 %, respectively). Furthermore, in early ST, death occurred at a significantly shorter interval than for early NSRMI.
Mechanisms behind these observations are not entirely clear although pathophysiologic explanations have been put forward. Some studies have suggested that, as opposed to early ST, very late ST is not related to lesion complexity (a prognostic marker) in index PCI but rather to neoatherosclerosis [13, 18] . It is also possible that in a STEMI context, where some degree of myocardial necrosis is invariably present, late ST and very late ST may not have the same impact as recurrent NSRMI has in a remote territory. Other factors hypothetically implicated in these observations, but not readily evident from our results, could be differences in management in favor of patients with late ST and very late ST in comparison with NSRMI owing to a higher perceived risk for ST.
The long-term cause of death in patients with STEMI remains uncharted. Epidemiological studies [31] with comprehensive national-based long-term follow-up have found that noncardiac causes are responsible for the majority of later deaths in STEMI patients. This is in line with our results, where we found that despite worse cardiovascular outcomes, patients with recurrent MI had a similar overall mortality to patients with no recurrent MI. Effective management strategies for recurrent MI are currently lacking. Secondary prevention studies testing enhanced anticoagulation regimens or systemic anti-inflammatory therapies have shown improvement in cardiovascular outcomes but at the expense of significant adverse events [31] [32] [33] . Therefore, more sophisticated patient or timing selection tools are needed to identify those who can benefit most from these innovative therapies and also to guide further research. 
Limitations
This study has some limitations. First, as a single-center study, there is a question about whether these results can be extrapolated. Long-term data from realworld reports describe results similar to those we have found (5-year mortality rates between 15 and 25 % and recurrent MI as high as 23 %) [25] [26] [27] [28] [29] [30] . The longterm prevalence of ST published in the literature varies and depends on aspects such as the definition and type of ST, the study era, the antiplatelet therapy strategy used, and the proportion of acute patients. In this study, where first-generation drug-eluting stents were used in almost half the population, the long-term cumulative rate of definite or probable ST (5.27 %) was fairly equivalent to what is usually described in the same circumstances (4-8 %) [19] [20] [21] [22] [23] [24] . Second, this is an exploratory analysis from a prospective MI registry. The registry was not specifically designed to answer the research question presented, and thus the results can only be considered as hypothesis-generating. Third, almost half of the cases classified according to the ARC criteria were considered probable ST, and therefore without confirmation by angiography or autopsy this could have led to an overestimation of the true incidence of ST. We could not determine the exact causes of extra-hospital deaths. Fourth, we did not include data related to adherence or compliance to medications, particularly regarding antiplatelet therapy. Thus, despite a similar baseline anti-platelet regimen, we cannot exclude the possibility that subsequent medical management could be different among the groups. Fifth, assessment of the extent of myocardial injury by quantification of cardiac biomarkers, left ventricular ejection fraction or, more importantly, scar quantification was not systematically evaluated in all patients at standardized time points and therefore was not analyzed. Finally, comparisons between patient subgroups may not have had adequate statistical power to detect significant differences owing to the limited number of patients with ST.
Conclusion
At long term after PCI for STEMI more than one third of patients had recurrent MI or death. NSRMI was 2.5 times more frequent than ST. Overall, rates of allcause and cardiac mortality were equivalentafterSTorNSRMI.However, timing of recurrent MI had a different impact on prognosis depending on the type of recurrent MI: a higher mortality for ST occurring in the first 30 days, but thereafter differences in mortality were not significant. In patients free from recurrent MI, cardiovascular events were lower than in patients with recurrent MI but all-cause mortality was comparable.
